Insulin glargine + lixisenatide
Indications & Dose:
INDICATIONS Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellituDOSAGE AND ADMINISTRATION
starting dosage is 15 units (15 units insulin glargine/5 mcg lixisenatide) given subcutaneously once daily.
- In patients inadequately controlled on 30 to 60 units of basal insulin, the starting dosage is 30 units (30 units insulin glargine/10 mcg lixisenatide) given subcutaneously once daily.
- Inject once a day within the hour prior to the first meal of the day. Maximum daily dosage is 60 units (60 units of insulin glargine and 20 mcg of lixisenatide). Use alternative antidiabetic products if patients require a combination 100/33 daily dosage below 15 units or over 60 units.
Contraindications:
Hypersensitivity
Side Effects:
-
Cautions:
-
Precautions:
-
Interaction:
-
Warnings:
WARNINGS AND PRECAUTIONS
Anaphylaxis and serious hypersensitivity reactions: Severe, lifethreatening, and generalized allergic reactions can occur. Instruct patients to discontinue if a reaction occurs and promptly seek medical attention.
- Pancreatitis: Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Never share a This drug 100/33 prefilled pen between patients, even if the needle is changed.
- Hyperglycemia or hypoglycemia with changes in This drug 100/33 regimen: Carry out under close medical supervision. Overdose due to Medication errors: This drug 100/33 contains two drugs. Instruct patients to always check the label before each injection since accidental mix-ups with insulin-containing products can occur. Do not exceed the maximum dose or use with other GLP-1 receptor agonists.
- Hypoglycemia: May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, coadminitered glucose lowering medications, meal pattern, physical activity and in patients with renal or hepatic impairment and hypoglycemia unawareness.
- Acute Kidney Injury: Monitor renal function in patients with renal impairment and in patients with severe GI adverse reactions. Use is not recommended in patients with end-stage renal disease.
- Immunogenicity: Patients may develop antibodies to insulin glargine and lixisenatide. If there is worsening glycemic control or failure to achieve targeted glycemic control, significant injection-site reactions or allergic reactions, alternative antidiabetic therapy should be considered.
- Hypokalemia: May be life-threatening. Monitor poyassium levels in patients at risk of hypokalemia and treat if indicated.
- Fluid retention and heart failure with use of thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs.
- Macrovascular Outcomes: Clinical studies have not shown macrovascular risk reduction with This drug 100/33.
Adverse Effects:
-
Lactations:
-
Special Precautions:
-
Counselling:
-
Side Effects Or Adverse Reactions:
Nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, headache.
Patient And Carer Advice:
-